FDA Grants Accelerated Approval to Iberdomide for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM). This combination is indicated for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Iberdomide is the first approved cereblon E3 ligase modulator (CELMoD) agent, introducing a potent, oral, novel drug class in the myeloma treatment landscape.